We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Carisma Therapeutics Inc | NASDAQ:CARM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06 | -5.26% | 1.08 | 1.08 | 1.20 | 1.14 | 1.07 | 1.12 | 116,217 | 23:56:56 |
Thursday 25 July 2024
Regulatory News:
Carmila (Paris:CARM) has signed a cash share buyback mandate with an investment service provider for a maximum amount of €10 million.
The purchase period will start on 29 July 2024 and end, at the latest, on 31 December 2024. The shares purchased will be held for future cancellation.
This operation falls within the framework of Carmila’s share buyback program, as authorized by the General Meeting of shareholders of 24 April 2024.
INVESTOR AGENDA
25 July 2024: First half 2024 results presentation 17 October 2024 (after market close): Financial information for the third quarter 2024
ABOUT CARMILA
As the third-largest listed owner of commercial property in Europe, Carmila was founded by Carrefour and large institutional investors in order to enhance the value of shopping centres adjoining Carrefour hypermarkets in France, Spain and Italy. At 31 December 2023, its portfolio was valued at €5.9 billion and is made up of 201 shopping centres, with leading positions in their catchment areas.
Carmila is listed on Euronext-Paris Compartment A under the symbol CARM. It benefits from the tax regime for French real estate investment trusts (“SIIC”). Carmila has been a member of the SBF 120 since 20 June 2022.
This press release is available in the “Share buyback program” section of Carmila’s Finance webpage: https://www.carmila.com/en/finance/share-buyback-program/
Visit our website at https://www.carmila.com/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724707779/en/
INVESTOR AND ANALYST CONTACT Pierre-Yves Thirion – CFO pierre_yves_thirion@carmila.com +33 6 47 21 60 49 PRESS CONTACT Elodie Arcayna – Corporate Communications Director elodie_arcayna@carmila.com +33 7 86 54 40 10
1 Year Carisma Therapeutics Chart |
1 Month Carisma Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
